Skip to content

Upjohn

Active Private limited companyfounded 2014active for 12 yearsTerhulpsesteenweg 6A, 1560 HoeilaartKBO/BCE: BE 0552.558.025 subsidiary of .#4 company by total assets in Flemish Brabant, Pharmaceuticals sector
Part of the group PFIZER INC. 25 companies in 18 countries
See the group

Annual accounts 2025

full format, filed on 07-07-2026, 24 days before the deadline
€944,124
▲ 15.8%
€920,506
▲ 26.1%
-
-
98.0%
▲ 2.0 percentage points
48.99
▲ 24.00

Money flows

no detail for 2025

Balance sheet

balance sheet total €12.3m on 31-12-2025
What the company ownsHow it is paid for

in €m

in euro

Position in the sector

98.0%

Higher than 95% of 61 companies in 2025.

48.99

Higher than 95% of 60 companies in 2025.

6.9%

Higher than 66% of 61 companies in 2025.

Upjohn Middle half of the sector 80% of the sector Full accounts in pharmaceuticals (NACE 21)

Net result: middle half · Equity: middle half · Balance sheet total: middle half · Working capital: middle half

Staff

Men and women

Not in that year's accounts.

Staff costs divided by the average number of full-time equivalents.

employees who joined employees who left

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend202520242023202213 months202120202019201820172016201519 months
Balance sheet: assets
20/58 12.3m11.7m11.1m25.1m26.1m45.3m25.0m93.0m96.7m78.4m96.7m
21/28 0000-3,740177,6366.9m9.3m--
21 0000---2.5m4.9m7.4m9.8m
28 -----3,740177,6364.4m4.4m4.3m11,550
280/1 -------4.2m4.2m4.2m-
280 -------4.2m4.2m4.2m-
284/8 -----3,740177,636183,966180,22631,83211,550
285/8 -----3,740177,636183,966180,22631,83211,550
29/58 12.3m11.7m11.1m25.1m26.1m45.3m24.8m86.1m87.3m66.7m86.8m
3 ----9.1m9.0m7.3m25.5m27.4m24.5m30.7m
30/36 ----9.1m9.0m7.3m25.5m27.4m24.5m30.7m
34 ----9.1m9.0m7.3m25.5m27.4m24.5m30.7m
40/41 12.3m11.5m10.9m24.0m7.8m6.9m4.7m17.5m18.4m18.7m20.0m
40 319,490557,664181,217587,2557.5m4.1m4.0m15.3m17.1m15.8m16.6m
41 12.0m11.0m10.7m23.4m266,7602.9m691,5452.2m1.3m2.8m3.4m
54/58 0171,622172,2781.2m9.0m29.3m12.4m42.4m40.9m22.9m35.5m
490/1 ----225,44367,372405,702701,332611,510672,137683,335
Balance sheet: equity and liabilities
10/49 12.3m11.7m11.1m25.1m26.1m45.3m25.0m93.0m96.7m78.4m96.7m
10/15 12.1m11.2m10.5m16.6m15.8m14.4m13.0m67.5m64.6m62.6m57.8m
10/11 6.4m6.4m6.4m6.4m6.4m6.4m-----
10 ------6.3m17.0m17.0m17.0m17.0m
100 ------6.3m17.0m17.0m17.0m17.0m
11 ------174,543473,425473,424473,424473,424
13 1.3m1.3m1.3m1.3m1.3m1.3m1.3m3.4m3.4m3.4m3.4m
130/1 3,8113,8113,8113,811629,102629,102-----
130 ------625,2911.7m1.7m1.7m1.7m
1311 ----625,291625,2913,81110,35910,35910,35910,359
1319 3,8113,8113,8113,8113,8113,811-----
132 625,603625,603625,603625,603625,603625,603625,6031.7m1.7m1.7m1.7m
133 627,735627,735627,735627,7352,4442,4442,4446,6426,6426,6426,642
14 4.4m3.6m2.8m8.9m8.1m6.7m5.3m46.6m43.7m41.7m36.9m
16 -------65,313888,0001.1m157,265
160/5 -------65,313888,0001.1m157,265
160 ----------157,265
164/5 -------65,313888,000--
17/49 252,075468,927628,9218.6m10.3m30.9m12.0m25.4m31.2m14.7m38.8m
42/48 252,075468,927628,9218.6m9.5m30.0m11.1m21.0m25.6m11.1m35.1m
43 -----15.3m-----
439 -----15.3m-----
44 175,626252,963266,6341.3m8.8m11.0m7.6m14.3m17.2m4.9m28.4m
440/4 175,626252,963266,6341.3m8.8m11.0m7.6m14.3m17.2m4.9m28.4m
45 69,0087,508128,278122,140724,5763.7m3.5m6.7m8.4m6.2m6.6m
450/3 69,0085,32391,921118,171129,5333.0m2.7m5.4m6.7m4.4m4.5m
454/9 02,18436,3573,970595,043753,297788,5001.3m1.7m1.8m2.1m
47/48 7,441208,457234,0097.2m-------
492/3 ---0778,681879,569924,2834.4m5.5m3.6m3.7m
Income statement
70/76A 944,124815,543973,53730.3m43.8m42.4m60.8m113.0m119.6m--
70 --4,77223.5m41.6m41.4m60.0m112.8m118.6m118.2m136.1m
74 944,124815,543968,7646.8m2.2m937,215810,691177,9881.1m2.4m3.1m
60/66A 23,61885,325185,44729.2m41.8m40.3m58.0m110.1m117.6m--
60 ---20.1m29.0m28.2m42.3m83.6m87.3m83.1m95.6m
600/8 ---10.3m-----77.9m99.2m
609 ---9.9m-994,001-1.6m4.1m2.8m-2.3m5.3m-3.6m
61 29,37979,938140,2231.4m4.5m6.9m7.9m9.8m12.8m12.9m21.4m
62 -5,7601,75617,3791.5m5.0m3.4m3.2m5.6m5.6m5.6m12.0m
630 ------1.3m2.5m2.5m2.5m2.5m
631/4 ----792,758766,56559,479-1.0m-893,294-445,1571.0m-1.6m
635/8 -------65,313-822,687-233,045--
640/8 03,63127,8447.1m2.5m1.7m4.4m10.3m10.1m9.8m10.4m
9901 920,506730,218788,0901.0m2.0m2.1m2.8m2.9m2.0m4.9m-1.2m
75/76B 244,311360,448412,27022,487-------
75 244,311360,448412,27022,4834,4915,681430,409623,542624,681538,586254
751 11,7282,849405,551--3,3143-3362
752/9 232,583357,5996,71922,4834,4912,367430,406623,542624,678538,550252
76B ---4-------
65/66B 8,4466,2448,13540,79460,88051,007446,220562,554607,334--
65 8,4466,2448,13540,79460,88051,007446,220562,554607,334583,8298,799
650 ---18,77957,77043,183500--27,30730
652/9 8,4466,2448,13522,0153,1107,824445,720562,554607,334--
9903 1.2m1.1m1.2m1.0m2.0m2.0m2.8m3.0m2.1m4.8m-1.2m
67/77 306,346303,323302,928257,803535,631639,562335,61177,5664,9124,8555,808
670/3 306,346303,323302,928257,803535,631641,352335,61177,5664,9124,8555,808
77 -----1,790-----
9904 850,025781,099889,297773,4091.4m1.4m2.5m2.9m2.1m4.8m-1.2m
9905 850,025781,099889,297773,4091.4m1.4m2.5m2.9m2.1m4.8m-1.2m
Appropriation of the result
9906 4.4m3.6m9.8m8.9m8.1m6.7m21.8m46.6m43.7m41.7m36.8m
14P 3.6m2.8m8.9m8.1m6.7m5.3m19.3m43.7m41.7m36.9m38.0m
791/2 ----------58,006
792 ----------58,006
694/7 --7.0m---16.5m----
694 --7.0m---16.5m----
Social balance sheet
9087 ---4.4212621.234.136.93641.2
Men (FTE)1003 ---1.8-------
Women (FTE)1003 ---2.6-------
Agency workers1501 ---0-------
Hours worked1013 ---6,523-------
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The notes to these accounts have 21 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the accounts filed with the NBB.

Source: Annual accounts 2025 at the NBB, filed on 07-07-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 full format 07-07-2026 2026-00269740 PDF
31-12-2024 full format 27-06-2025 2025-00225752 PDF
31-12-2023 unclassified schema 27-06-2024 2024-00215314 PDF
31-12-2022 unclassified schema 03-08-2023 2023-00319447 PDF
30-11-2021 unclassified schema 09-06-2022 2022-20071571 PDF
30-11-2020 unclassified schema 03-06-2021 2021-18200368 PDF
30-11-2019 full format 29-06-2020 2020-22200469 PDF
30-11-2018 full format 22-05-2019 2019-14600338 PDF
30-11-2017 full format 30-05-2018 2018-15300160 PDF
30-11-2016 full format 09-06-2017 2017-16800385 PDF
30-11-2015 full format 15-06-2016 2016-19000192 PDF

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend202520242023202213 months202120202019201820172016201519 months
------4.1m5.4m4.5m7.3m1.3m
------3.7m5.3m4.5m7.3m1.3m
-------5.5m3,741148,3944.2m12.3m
-171,622-656-1.0m-7.8m-20.3m17.0m-30.0m1.4m18.0m-12.5m-
12.1m11.2m10.5m16.6m16.6m15.3m13.7m65.1m61.7m55.6m51.8m
---4.5%4.9%5.0%4.7%2.6%1.7%4.1%-0.9%
98.0%96.0%94.3%66.0%60.5%31.7%51.9%72.6%66.8%79.8%59.7%
48.9924.9817.642.942.741.512.244.103.415.992.48
48.9924.9817.642.941.791.211.582.892.343.801.60
0.020.040.060.520.652.150.930.380.480.230.67
7.0%6.9%8.5%4.7%9.0%9.7%19.0%4.3%3.2%7.7%-2.0%
6.9%6.7%8.0%3.1%5.5%3.1%9.9%3.1%2.1%6.1%-1.2%
------over 1009.527.41over 100over 100
--over 999 days9 days66 days36 days25 days49 days53 days49 days45 days
over 999 daysover 999 days694 days22 days96 days114 days55 days56 days63 days19 days89 days

EBIT margin not meaningful, as turnover is only a small part of operating income.

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Revenue breakdown

as filed

By activity 2023

  • Ventes de produits pharmaceutiques €4,772100.0%

Source: 2023 accounts, page 17, filing 2024-00215314

All years (2021 to 2023)
By activity202120222023
Ventes de produits pharmaceutiques€41,570,143€23,484,859€4,772

Social balance sheet

Item31-12-2022
Employees at the balance-sheet date0
full-time0
part-time0
in full-time equivalents0
4.4
On a permanent contract0
Joined0
Left21
Agency workers, average number0
Training hours0

Source: social balance sheet in the 2022 annual accounts

Auditor

fees
Item202520242023202230-11-2021
Fee for the audit€22,180€22,850€22,100€50,600€46,000

Source: notes to the 2021 to 2025 annual accounts (relations with the auditor)

Public contracts

1 award · 2026
Raamovereenkomst voor het leveren van anesthetica: Esketamine
buyer: Universitair Ziekenhuis GentMedical equipment and pharmaceuticalsawarded 21-09-2026€76,0862 tendersTED 657650-2026

Source: TED (Tenders Electronic Daily), Publications Office of the European Union. The values are as the buyer published them. For a framework agreement, the value is a ceiling.

Insights on Upjohn

The operating result for 2025 is 26% higher than in 2024 and the highest since 2022. It is a recovery after the fall in 2024.

Debt's share of the balance-sheet total falls from 4.0% to 2.0%. Equity is higher and debt is lower.

Large changes and their cause
  • 2023 Turnover -100% on 2022. The previous financial year ran 13 months, this one 12.

Next steps